We have some important companies with Palantir, Super Micro computer, Block, Moderna, Qualcomm, Arista Networks, Gilead Sciences and Airbnb all set to report.
Thursday, October 31, 2024Jobs Week trudges along this morning, with Friday morning’s big Employment Situation report now on the horizon. Behind this stands the 2024 General Election — which could...
Economic & Earnings CommentaryJobs Week trudges along this morning, with Friday morning’s big Employment Situation report now on the horizon. Behind this stands the 2024 General Election — which could...
BMY earnings call for the period ending September 30, 2024.
This article highlights a standout healthcare REIT that offers investors a strong 5% dividend yield.
These two growth stocks could be great additions to a long-term buy-and-hold portfolio.
After more than doubling in the past year, is this clinical-stage biotech stock still a buy?
/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
Bristol-Myers Squibb is gearing up to release its third-quarter earnings at the end of this month, and analysts expect a double-digit profit dip.
Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.
Last week, Bristol Myers BMY obtained FDA approval for a label expansion of its blockbuster immuno oncology drug Opdivo (nivolumab).The FDA approved Opdivo as a perioperative treatment regimen for adults...